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Summary 
The human immunodeficiency virus (HIV)-infected patient is more prone to developing both 
acute and chronic renal failure than the general population. Renal disease specific to the HIV-
infected population include HIV-associated nephropathy (HIVAN), mostly prevalent in the 
black population, and HIV immune complex kidney disease (HIVICK), which is more 
common in the white population. Some immune complex diseases of the kidney are thought, 
in the majority of cases, to originate from a co-infection with hepatitis C virus (HCV). As the 
life expectancy of this population is getting longer they are more likely to suffer from end 
organ damage due to age related diseases such as hypertension (HTN) and diabetes mellitus 
(DM). The  kidney function can be monitored by estimated glomerular  filtration rate (eGFR), 
albumin/creatinine ratio (ACR) and protein/creatinine ratio (PCR). Using ACR and PCR 
enables estimation of the renal function even in dilute urine and does not need sensitive lab 
machines, necessary for detecting tubular proteins in urine, that are not available at many 
hospitals. Treatment of established kidney disease is by managing modifiable factors, such as 
HTN, body weight and drug regimen as far as possible. Renal replacement therapy is 
indicated as for other patient groups with decreased renal function. If the patient fulfil certain 
criteria they are eligible for a renal transplant. Social stigma and lack of knowledge has led 
fewer HIV-infected patients to want transplantation. Among the HIV-specific criteria for 
transplantation include that the patient has to be well regulated with combined ART (cART) 
for at least six months and without a history of opportunistic infections. Immunosuppressive 
(IS) therapy was for a long time thought to enable the virus to freely replicate and hasten the 
progression to AIDS and death. Studies have later shown that by suppressing the immune 
system one is preventing activation of CD4+ T cells and, because the HIV-virus infect 
activated cells, they also protect new T-cells from being infected. IS may thus, on the 
contrary, even be beneficial in these patients. The drug interactions between IS and ART are 
many and complex and it is beneficial with multidisciplinary teams, including a infectologist 
and nephrologist, to choose the optimal therapy. Blood levels of the drugs should be checked 
with regular intervals to ensure therapeutic levels and prevent nephrotoxicity or rejection. The 
outcome after transplantation is continuing to improve. The frequency of rejection episodes is 
higher in this population, but the graft and patient survival is similar to the general population. 
Meta-analyses have concluded that renal transplantation should be offered to patients who 
fulfill the criteria, although the strength of evidence is very low due to small study samples.  
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Acronyms 
 ART  Anti-retroviral therapy 
 cART  Combined ART 
 HAART  Highly active ART 
 IS  Immunosuppressant 
 PI  Protease inhibitors 
 NNRTI  Non-nucleoside reverse transcriptase inhibitor 
 NRTI  Nucleoside reverse transcriptase inhibitor 
 EFV  Efavirenz 
 NVP  Nevirapine 
 CsA  Cyclosporine A 
 TAC  Tacrolimus 
 HTN  Hypertension 
 DM  Diabetes mellitus 
 HIV  Human immunodeficiency virus 
 HIVAN  HIV-associated nephropathy 
 RRT  Renal replacement therapy 
 ARF  Acute renal failure 
 AKI  Acute kidney injury 
 CKD  Chronic kidney disease 
 GFR  Glomerular filtration rate 
 eGFR  Estimated glomerular filtration rate 
 ESRD  End-stage renal disease 
 NSAID  Non-steroidal anti-inflammatory drug 
 ACE inhibitor Angiotensin converting enzyme inhibitor 
 ARB  Angiotensin receptor blocker 
 HCV  Hepatitis C virus 
 HBV  Hepatitis B virus 
 PCR  Protein-Creatinine ratio 
 ACR  Albumin-Creatinine ratio 
 CG  Cockroft-Gault 
 CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
 MDRD  Modification of Diet in Renal Disease 
 LDKT  Living donor kidney transplantation 
 GALT  Gut associated lymphoid tissue 
 PRA  Panel reactive antibodies 
 NSTEMI  Non-ST elevation myocardial infarction 
 CNI  Calcineurin inhibitors 
 BMI  Body mass index 
 HSCT  Hematopoietic stem cell transplantation 
 HiB  Hemophilus influenza type B 
 CMV  Cytomegalovirus 
 PCP  Pneumocystis carinii pneumonia 
 NODAT  New onset of diabetes mellitus after transplantation 
 RCT  Randomized control trial 
 DGF  Delayed graft function 
 AUC  Area under the curve 
 STI  Sexually transmitted infection 
 UTI  Urinary tract infection 
 TMP-SMX Trimethoprim-Sulfamethoxazole
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Summary of drugs 
Immunosuppressants 
Calcineurin-inhibitors / IL-2 inhibitors 
 Cyclosporine A 
 Tacrolimus 
Anti-metabolites 
 Mycophenolate mofetil 
m-TORs 
 Sirolimus 
 Everolimus 
Anti-lymphocyte antobodies 
 Thymoglobulin 
 Anti-thymocyte globulin 
Anti-CD25 monoclonal anti-lymphocyte 
antibody 
 Basiliximab 
Corticosteroids 
 Methylprednisolone 
 Prednisone 
 
 
Antiretrovirals 
Nucleoside reverse transcriptase (NRTIs) 
 Abacavir 
Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) 
 Zidovudine 
 Didanosine 
 Efavirenz 
 Nevirapine 
 Emtricitabine 
 Lamivudine 
 Stavudine 
 Tenofovir 
Protease inhibitors (Pis) 
 Indinavir 
 Saquinavir 
 Nelfinavir 
 Ritonavir 
 Fosamprenavir 
 Lopinavir 
 Atazanavir 
 Tipranavir 
 Darunavir 
CCR 5 Co-receptor agonist 
 Maraviroc 
Fusion inhibitors 
 Enfurvitide 
Integrase inhibitors 
 Raltegravir 
 Dolutegravir 
 Elvitegravir/Cobicitat 
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Co-formulated agents 
 Combivir 
 Lamivudine/Zidovudine 
 Epzicome 
 Abacavir/Lamivudine 
 Trizivir 
 Abacavir/Lamivudine/Zidovudine 
 Atripla 
 Efavirenz/Emtricitabine/Tenofovir 
 Complira 
 Emtricitabine/Rilpivirine/Tenofovir 
 Stribild 
 Elvitegravir/Cobicistat/Emtricitabine/
Tenofovir 
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Introduction 
The life span of a person infected with human immunodeficiency virus (HIV) has 
significantly improved since its appearance in the 1980's, and is now approaching that of the 
general population. This has consequently led to a higher prevalence of age related diseases 
that also affect kidney function, such as hypertension (HTN) and diabetes mellitus (DM). 
Apart from those conditions there are other factors more specific to the HIV-infected 
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population with nephrotoxicity due to antiretroviral drugs, HIV-associated nephropathy 
(HIVAN) and immune complex-mediated glomerulonephritis to mention some. Although the 
prevalence of HIV-infected patients requiring renal replacement therapy (RRT) in Europe is 
fairly low, it is increasing due to the aforementioned factors. Patients infected with HIV were 
for a long time not considered eligible for renal transplantation due to fear that the subsequent 
immunosuppressive therapy would increase viral load and hasten the progression of their 
infection. With the introduction of highly active anti-retroviral therapy (HAART), increasing 
knowledge about the pathophysiology of the disease and novel immunosuppressive 
medication in the 1990's, transplantation results were not much worse in comparison with the 
HIV-negative population. One obstacle that remains still is the higher frequency of delayed 
graft function and acute rejection in this patient group, but constant development in 
knowledge and understanding of the immunosuppressive agents keep improving the outcome 
in this population. Renal transplantation is a treatment option that should be considered after 
individual evaluation of each patient with HIV and end-stage renal disease (ESRD). 
 
History of HIV/AIDS 
On June 5th 1981, the Center for Disease Control in the U.S. published a Morbidity and 
Mortality Weekly Report describing the finding of infections attributed to a non-functioning 
immune system in five apparently healthy young gay men in Los Angeles. Shortly thereafter 
more case series followed. In the next year, more than tens of thousands were appreciated to 
be infected, and the term Acquired Immune Deficiency Syndrome was coined on September 
24th 1982. The definition was then “a disease at least moderately predictive of a defect in 
cell-mediated immunity, occurring in a person with no known cause for diminished resistance 
to that disease.”, but it was not until 1986 that the virus was named Human Immunodeficiency 
Virus, HIV. One year later, and six years after the first report of acquired immuno deficiency 
syndrome (AIDS), Food and Drug Administration (FDA) approves the first antiretroviral 
drug: Zidovudine. By 1994, AIDS had become the leading cause of death in all Americans in 
the age between 25 and 44 years. In 1995, the first Protease Inhibitor was FDA approved and 
we enter the era of HAART. The following year, AIDS was no longer the leading cause of 
death in the young and previously healthy, except in the African American population, and 
the world is for the first time feeling careful optimism. In 1997, 47% less patients died of 
AIDS or AIDS-related diseases than the previous year, which was mostly attributed to the 
introduction of HAART. Combination pills are starting to be produced to increase 
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compliance, the first Non-Nucleoside Reverse Transcriptase, NNRT, was approved, but 
resistance starts to become a problem.  
As the HIV/AIDS epidemic is starting to get under control in the U.S., Canada and Europe, 
reports on major spread on the African continent are appearing and it is the number one killer 
in their whole population. The UNAIDS (the joint United Nations programme on AIDS) 
reports in 2002 that the average life expectancy has decreased from 62 to 47 years solely due 
to HIV/AIDS.
1 
 
Etiology of impaired kidney function in patients with HIV/AIDS 
Kidney disease can be classified as acute or chronic: glomerular, vascular or tubulointerstitial. 
HIV-infected patients may develop nephropathies due to many reasons such as a secondary 
cause of the virus itself, the antiretroviral therapy and/or some co-infection with e.g. hepatitis 
C. 
 
 
Table 1. Kidney disease associated with human immunodeficiency virus (HIV) infection. 
Shown are diseases that are associated with HIV infection or its treatment. *Certain 
glomerular diseases are commonly associated with other viral infections or may occur on an 
idiopathic basis; a true association with HIV disease is uncertain or doubtful. Collapsing 
glomerulopathy is notable for glomerular, tubular and interstitial disease but is classified under 
glomerular disease for simplicity. According to Johnson RJ, Feehally J, Floege J (2015), p.683 
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Acute renal failure 
Acute renal failure (ARF) is defined differently across studies, but a consistent feature is a 
drop glomerular filtration rate (GFR) with subsequent sequelae such as electrolyte 
derangements, encephalopathy and volume overload that may have a fatal outcome.
2
 In a 
study where ARF was investigated in HIV positive patients it was found that 6 % of their 
inpatients had ARF with a mortality rate of 27 %. The incidence in the outpatient group the 
incidence was up to 10 % with approximately one third secondary to drugs
3
 but HIV infection 
by itself had also been associated with ARF
4
. One study found that more than half of the 
episodes of ARF were attributed to infection with 76% of these being an AIDS-defining 
illness.
5
  
Chronic kidney disease 
Chronic kidney disease (CKD) is defined as a decrease in GFR <60ml/min/1.73m² or renal 
damage (proteinuria, albuminuria, histological abnormalities in the biopsy, the urinary 
sediment or imaging techniques) that persists for more than three months.
6
 Risk factors for 
CKD include HTN, DM, advanced age, a low CD4 nadir, a high HIV viral load and the use of 
potentially nephrotoxic medication.
7-11
 The prevalence differs with ethnicity and is higher in 
areas with less access to treatment.
12
 Kidney Disease Improving Global Outcomes (KDIGO) 
proposed a new classification for prognosis of CKD in 2012 including GFR and albuminuria; 
the patients are  divided into six categories depending on the urinary albumin/creatinine ratio 
(ACR) and eGFR. The risk outcome events include overall mortality, cardiovascular 
mortality, renal failure treated with dialysis or transplantation, ARF and progression of renal 
disease.
13, 14
 Approximately 7.1 % of HIV-infected patients have an estimated GFR (eGFR)
12
 
<60ml/min/1.73m
2 
and the prevalence of albuminuria have been measured in several studies 
to between 11 % and 15.5 %.
15
  
 
Antiretroviral drug-induced nephrotoxicity 
Nephrotoxicity as a consequence of antiretroviral therapy is uncommon today, although it is 
suspected that it will increase along with the aging of the population. The risk of having a 
decrease in eGFR is mostly associated with Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs), with Tenofovir (TDF) in particular, and Protease Inhibitors (PIs), such as 
Atazanavir (ATV) and Lopinavir (LPV). The higher risk of renal toxicity with the above 
mentioned drugs is controversial and may be due to drug interactions in between the 
antiretroviral drugs. The toxicity causes functional abnormalities of the tubular proteins, 
    
 
12 
 
mainly in the proximal part, causing a clinical picture similar to Fanconi syndrome. This, in 
full, include phosphaturia, glucosuria with normoglycemia, renal tubular acidosis with normal 
anion gap, aminoaciduria, tubular proteinuria and medium-long-term renal failure.
16-22 
The 
damage caused by TDF toxicity is usually reversible, but may not be complete.
23 
One center 
reported that the administration of TDF each year resulted in a 34 % increased risk of 
developing proteinuria, 11 % increased risk of rapid decline and a 33 % increased risk of 
CKD
24
. Several studies have shown specific toxicity of TDF when used in combination with 
certain drugs, for example Didanosine. It has been suggested that it might be of greater benefit 
to regulate the combination of drugs than to exclude TDF, which has demonstrated a positive 
effect in several randomized control trials. This strategy requires a regular monitoring of 
kidney function.
25
  
 
 
Table 2. Renal toxicity of antiretroviral therapy. Effects of toxicity and their management. 
According to Johnson RJ, Feehally J, Floege J (2015), p. 685 
 
 
Non-antiretroviral drug-induced nephrotoxicity 
HIV infected persons might need other drugs during the course of life that are nephrotoxic. 
This might be due to co-morbidities, opportunistic infections or non-HIV-related conditions. 
The groups of drugs most commonly implicated are certain Antiobiotics and Antivirals, Non-
steroidal Anti-inflammatory drugs (NSAIDs), angiotensin converting enzyme (ACE)-
inhibitors/angiotensin receptor blockers (ARBs) and iodinated contrasts. These drugs, if 
possible, should be avoided or dose adjusted according to current kidney function.
2
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Glomerular and vascular nephropathies 
The spectrum of glomerular pathologies is wide and dependent on race, co-infection with 
Hepatitis C (HCV) virus or any other co-infection, and the control of their HIV. In previous 
years HIV associated nephropathy (HIVAN) was more prevalent, whereas today older age 
and cardiovascular causes are more prominent.
26
 
HIV-associated nephropathy  
HIV-associated nephropathy (HIVAN) is the best defined type of nephropathy in this 
population. It is characterized by a focal and segmental collapsing glomerulosclerosis on 
histology. Clinically the main manifestation is proteinuria, which frequently reaches over 
3.5g/24h, although the clinical impact seems to be less severe than patients with other causes 
of nephrotic syndrome.
27
 It is more prevalent in the Black than the Caucasian patients with a 
ratio of 12:1.
28, 29 
The higher prevalence of HIVAN in the black population has been 
associated with a variant in APOL1 gene. This gene is protecting against trypanosomiasis, but 
has also been shown to increase the risk of developing kidney disease.
30, 31
 The outcome of 
HIVAN without ART is poor, often with progression to renal failure requiring dialysis within 
one year of diagnosis and a high mortality rate.
32
 Since the introduction of combined ART 
(cART), the clinical course has improved.
33
 Several observational studies have shown a 
reduced risk of developing HIVAN and improved prognosis with ART, but until today no 
controlled clinical trials have been performed.
33-37
 Treatments including ACE-inhibitors or 
ARBs may delay progression to renal failure. They are indicated when HIVAN is associated 
with hypertension or proteinuria.
38
 Some studies showed the benefit of steroid therapy in 
slowing down the progression to renal failure, but this may in addition to the known side 
effects be particularly problematic in patients with impaired immunity
39
 and is not used 
routinely
2
, but only when it is resistant to therapy with ART and ACE-inhibitor/ARB.
39
 
HIV-associated immune complex kidney disease (HIVICK) 
Impaired renal function due to deposits of immune complexes is more common in the HIV-
infected persons than in the general population. HIVICK is a histological diagnosis that can 
have different etiologies with the HIV- infection itself being a cause, post-infectious 
glomerulonephritis
40
 or a co-infection with HBV- or HCV-infection. Histological appearance 
is varied, but the clinical manifestations are usually very apparent with macroscopic 
hematuria, edema, ARF and severe hypertension.
2
 IgA deposits are thought to be a direct 
consequence of the HIV infection.
41
 Sometimes other more discrete manifestations occur 
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including cryoglobulinemia with evidence of purpura, digestive symptoms and alveolar 
hemorrhage. Some of these lesions show deposits of IgG and IgM complexes usually 
associated with HCV-infection, and it has been suggested that this is in fact induced by the 
HCV infection with the HIV-infection having a marginal role. 
42-44 
Data on the natural history 
of HIVICK, treatment options and response to cART are limited 
45-49
, and it is not known 
whether or not it can be modified through therapies used in HIV-negative patients such as 
steroids, immunosuppressants and calcineurin inhibitors. In the cases where there is a HCV 
co-infection studies have shown improvement of renal function with effective anti-hepatitis 
therapy including Ribavirin and alpha-interferon. 
44, 50
 
Diabetic nephropathy and hypertensive nephropathy 
The metabolic consequences of antiretroviral therapy include dyslipidemia, body fat changes, 
insulin resistance and DM. These features are common in the general population as well and 
tend to increase with age. In the general population the cause of ESRD due to DM and HTN 
today is as high as 70 %.
51
 With the improvement of ART and longer life expectancy it is 
likely that these features will become more evident in the HIV- infected population as well. 
Some series of kidney biopsies have shown diabetic nephropathy in 6 % and hypertensive 
nephropathy in 4 %. 
52, 53
 Albuminuria is an independent risk factor for both cardiovascular 
disease and renal disease
54
,
 
and because it has a high prevalence in the HIV-infected 
population
15
, the
 
incidence in renal disease can be expected to increase in the future.
2
  
 
Monitoring kidney function 
Risk factors for CKD can be classified as modifiable and non-modifiable. The non-modifiable 
risk factors include race, genetic predisposition and age. The main modifiable risk factors are
2
  
 Body weight,  
 Concomitant illnesses (hypertension, diabetes mellitus, chronic HBV or HCV),  
 Use of potentially toxic drugs (ART: tenofovir, indinavir; Other: NSAIDs, 
aminoglycosides, amphotericin B, cidofovir, co-trimoxazole sulfadiazine, acyclovir, 
foscarnet),  
 HIV associated factors (viral replication, CD4+ lymphocyte nadir <200 cells/μl, 
previous diagnosed AIDS).  
By keeping the kidney function under control, one can detect renal disease early and adjust 
the therapy as needed. A basic renal study should include measuring of serum creatinine 
concentration and eGFR, protein/creatinine ratio (PCR) and albumin/creatinine ratio (ACR) in 
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the case of hypertension or diabetes, in the first morning urine. Urinary sediment and 
evaluation of tubular function should also be investigated.
2
 
 
 
Table 3. Management algorithm for screening of human immunodeficiency virus (HIV)-
infected antiretrociral therapy-naive patients for chronic kidney disease. Tuberculosis 
may be pulmonary or extrapulmonary. Antiproteinuric agents may be used in normotensive 
individuals with gradual uptitration of dose, depending on tolerance and severity of 
proteinuria. eGFR calculated by CG or MDRD. According to Johnson RJ, Feehally J, Floege J 
(2015), p. 685 
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Creatinine Clearance and eGFR 
Mocroft et al. compared the estimation of GFR using Cockroft-Gault (CG) and the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) estimating equations in HIV 
infection to see if anyone correlated better with kidney function, end-stage renal disease or 
deaths from kidney disease and all-cause mortality.
55
 The two most used formulae today are 
the Modification of Diet in Renal Disease (MDRD) and the CKD-EPI, which estimate the 
glomerular filtration rate
56
, whereas the Cockroft-Gault formula estimates creatinine 
clearance. The authors measured eGFR in 133 873 patients with CK standardized for body 
surface area (BSA) and CKD-EPI and out of them 85.7% were the same with both formulae. 
The agreement was considerably lower when CK was not standardized for BSA. The cases 
with discordant measures were more common in those co-infected with HCV, the non-white 
and those with unknown HIV exposure. In conclusion, they found that CG and CKD-EPI 
performed equally well in predicting ESRD and all-cause mortality.
55
 Levey et al. found that 
CKD-EPI was better at estimating GFR than MDRD, especially at higher levels and thus 
allowing earlier detection and intervention.
57
 The CG have traditionally been used to calculate 
drug dosages, using serum creatinine concentrations
58
. Although with limited studies 
performed on eGFR as measurement, some suggest that MDRD gives a good estimation for 
drug adjustments and can be used instead of CG.
59, 60 
 
Protein/creatinine (PCR) or albumin/creatinine ratio (ACR) 
Small increases in proteinuria usually precede an increase in serum creatinine and decrease in 
GFR. Gupta et al. found a correlation with proteinuria in first urine and development of 
ESRD.
61
 Szczech et al. noticed that up to 30 % of their subjects had proteinuria and found risk 
factors to be elevated HIV RNA level, low CD4+ cell count (<200cells/mm
3
), black race, and 
the presence of HCV antibodies.
62
 Hypoalbuminemia was identified as an independent risk 
factor for the development of ESRD, just as the previously mentioned HIV-associated factors, 
hypertension, diabetes and cardiovascular disease.
63
 This shows the clinical significance of 
following the PCR or ACR. There are different types of proteinuria and it is important to 
differentiate them.  
 Glomerular proteinuria: Proteins found in urine are mostly albumin, commonly 
caused by hypertension and diabetes. 
 Tubular proteinuria: This type of proteinuria is secondary to tubular toxicity and more 
often associated with antiretroviral therapy. Proteins found in the urine are usually of 
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low molecular weight such as α1-microglobulin, β2-microgloblin, retinol-binding 
protein, n-acetyl β-glucosamidase or neutrophil gelatinase-associated lipocalin. 
 Mixed proteinuria: This occurs when there is co-existence of both pathogenic 
processes.  
The procedures for measuring protein in urine are more sensitive for albumin than low 
molecular weight proteins, which must be present in fairly high concentrations to be 
detected.
64, 65
 In a study carried out in HIV positive patients, 21% of patients with proteinuria 
>300mg/g did not test positive with the test strip, but with but were detected when using 
PCR.
66
 Many laboratories do not have the technology to detect low molecular weight proteins 
and the use of ACR can distinguish protein of glomerular origin from that of tubular. By 
expressing protein content in urine in ratios, estimation errors from using dilute samples can 
be avoided.
2, 67 
  
 
Renal replacement therapy (RRT) 
Until 2001, chronic dialysis was the only available treatment for HIV-positive patients with 
ESRD in the United States. In Kumar et al. they found that the patient survival at one and two 
year post transplant was 85 % and 82 % respectively
68
, whereas studies of survival of HIV-
positive patients on dialysis have been found to be much lower, 58% and 41% at one and 
three years respectively.
69
 Between 1990 and 1999, the 1 year survival of HIV-infected 
patients on dialysis improved from 56% to 74%. Ahuja et al. investigated the survival of HIV 
positive patients on dialysis to see if the improved survival in the whole population after 
introduction of HAART applied to those on RRT as well. Until this time RRT did not seem to 
provide any survival benefit in patients with AIDS, but only in those with still asymptomatic 
HIV. The poor survival rate made it questionable whether to put HIV infected patients on 
RRT at all.
70
 The study showed that survival improved from 1997 (two years after HAART 
was introduced and the same year as it became treatment standard) and onward, but not to the 
same proportion as in the HIV-negative dialysis patients. One possible mechanism could have 
been the unknown pharmacokinetic effects of the ART in dialysis.
69
 Trullás et al. made a 
nationwide multicenter retrospective cohort study of HIV-infected patients on dialysis 
between 1999 and 2006 in Spain. The subjects were matched with a control group for age, 
year of starting dialysis, sex, race and dialysis center. The HIV-positive patients five year 
survival was lower than their HIV-negative counterpart 62.7% and 94.4 %, respectively. The 
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HIV-positive group was also less likely to be put on the waiting list for transplantation, 17% 
versus 64 % and less likely to be transplanted.
71
  
Antiretroviral dosing in patients with renal dysfunction/on dialysis 
Today there are guidelines on how to adjust dosing of ART in patients with decreased kidney 
function; both for those with primary ESRD and those who already received a kidney 
transplant but later again experienced deteriorating function. The majority of proton pump 
inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized 
by the liver and does not require any adjustment in kidney disease.
72
 The NRTIs on the other 
hand are mainly eliminated by the kidneys, both by glomerular filtration and tubular secretion. 
Dose adjustment in patients with impaired kidney function is important because some of them 
have nephrotoxic effects, e.g. Tenofovir. NNRTIs do not bind to proteins to a large extent and 
thus are easily removed by dialysis. PIs on the other hand are extensively bound to plasma 
proteins and cannot be cleared by dialysis. In Spain HIV-positive patients represent about 
0.5% of all patients on dialysis.
2
 The majority are on hemodialysis, but no survival benefit has 
in general been reported in either hemodialysis or peritoneal type.
73
  
 
Renal transplantation 
The history of organ transplantation started in 1906 when kidneys from different animals were 
used. Thirty years later human cadaveric kidney transplantation was tried, but it failed due to 
the fact that the donor and recipient had different blood type. In 1944, the British scientist, Sir 
Peter Medawar, discovered that rejection was due to immunologic factors and paved the way 
for the first successful kidney transplantation in 1954
74
. It was performed on identical twins at 
the Peter Bent Brigham Hospital, in the United States. After this, other organ transplantations 
followed with improvements in technique and immunosuppressive therapy. In 1983, 
cyclosporine was approved by FDA and, when administered with corticosteroids, it 
revolutionized the transplantation medicine. In 1994, tacrolimus was approved further 
improving outcome and decreasing side effects. In the mid 1990's the question about living 
donor transplantations was raised due to the organ scarcity. Mycophenolate mofetil was added 
to the market of immunosuppressives in 1995 and in 1999 sirolimus also. In 2001, the number 
of living donor organ donations surpassed cadaveric transplantation for the first time in the 
U.S.
75
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Eligibility for the waiting list 
Spital et al. sent out a questionnaire in 1998 to 248 transplantation centers in the U.S. 
regarding their willingness to put an HIV positive person on the waiting list. All centers 
answered that they required an HIV test prior to considering transplantation. The result from 
the questionnaire showed that an HIV-positive patient, who would otherwise be considered 
good candidates, would be denied a cadaveric transplant in 88 % of the centers and a living 
transplant in 91 %.
76
 The poor outcomes reported before the HAART-era made their 
impression on the transplant community and for a long time it was questionable as to whether 
or not it was morally acceptable to perform such invasive procedure with low chance of 
success implied that it would be a waste of organs. 
41, 68, 77 
The later trials showed good 
outcomes and similar results to the general population was slowly changed the attitude 
towards transplantation in the HIV-infected. Now, many guidelines recommend 
transplantation in the carefully selected patient.
2
 
72
 
Sawinski et al.reported that HIV-positive patients are less likely to be put on the waiting list 
for a transplant. Only 20% of theoretical HIV-positive patients were included on the list 
compared to 70% in the HIV-negative group over the same period of time. They examined the 
barriers and found several possible factors for this, including lack of documentation of HIV 
control, CD4+ <200cells/ml
3
, history of drug use, and African American race
78
. According to 
the Scientific Registry of Transplant Recipients (SRTR) among the HIV-positive recipients 
only 33 % of the recipients of living donor organs and 42 % of cadaveric donor organs were 
of African American descent
79
 although they tend to represent over 80 % of the persons with 
ESRD within the HIV-positive population.
80
  
Specific clinical criteria in the HIV-positive patient considered to be important for a 
successful transplantation are
79
 
 Be free of opportunistic infections 
 Compliant with therapy 
 Controlled with cART 
 Control of CD4+ count > 200 cells/mm3 for at least six months prior to transplantation 
 Patients with HBV or HCV co-infection need an additional evaluation by a 
hepatologist to ensure good liver synthetic function prior to kidney transplantation 
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 Absence of opportunistic infections or malignancy including a history of progressive 
multifocal leukoencephalopathy, lymphoma, pulmonary aspergillosis, significant 
Kaposi sarcoma, or coccidiomycosis, but every case should be evaluated individually 
A history of opportunistic infections is not necessarily a contraindication, but those mentioned 
in the paragraph are since these cannot be treated in an immunocompromised patient.
41
 The 
CD4+ cell count is an important marker of success, with the limit generally set on 200 
cells/mm
3 
for four to six months prior to the transplant and the HIV-RNA should be 
undetectable, at least <50 cells/ml.
77
 Ideally the patient should not have had an AIDS-defining 
event and had a psychiatric evaluation. Inclusion criteria for the waiting list are an HIV-
infected individual with CKD on RRT or in pre-dialysis phase who meet the general criteria 
after renal transplantation evaluation and HIV-specific criteria are passed.
2
  
Rodrigue et al. examined the willingness of HIV-positive patients to pursue living donor 
kidney transplantation (LDKT) in comparison to non-infected.
81
 Standardized questionnaires 
were given to HIV-infected and one non-infected control, matched by year of evaluation, age, 
sex, race and waiting time was included in the study. They found that the non-infected 
patients were mostly concerned if they would die if a living donor could not be found. The 
HIV-positive patients were concerned that no one would volunteer to be a living donor and 
they would feel guilty if a possible donor was found. They were afraid that the donor of the 
transplant would be pressured to donating or that the transplant center would be angry with 
family members if they would not agree to donate. In addition, the HIV-positive group had 
less knowledge about transplantation and donors than their non-infected counterpart. This 
included information about donor status, how quickly a donor can return to work, and that 
kidney donation typically does not increase the risk of future kidney failure. In the non-
infected group, 42% considered LDKT, compared to 21 % in the HIV-positive group.
81
 Some 
transplant programs require disclosure of HIV status to potential donors, whereas others do 
not. The social stigma of having HIV is still very much present today and the study found that 
most of the patients saw their HIV-status as a barrier to LDKT and felt uncomfortable sharing 
this information with a potential donor.
82, 83
 The lack of knowledge regarding living donor 
kidney transplant surprised the authors since the same information was offered to everyone 
regardless of HIV-status and they speculated that it might reflect their reluctance to pursue 
this option due to the perceived barrier of their infection. Another fact that stood out was that 
most HIV-positive patients did not know the current outcomes after kidney transplantation 
and might therefore be less likely to consider it. The fear of having to disclose their HIV 
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status, limited knowledge about the possibilities and outcomes of transplantation, and social 
stigma seem to explain why HIV infected patients are less likely to consider LDKT.
81
  
 
The impact of immunosuppression on HIV replication 
A reason many did not consider renal transplantation in the HIV-positive patient is the notion 
that the post-transplant immunosuppressive therapy would lead to progression of the HIV 
disease.
84
 Further studies on the action of immunosuppressive therapy (IS) in HIV-infected 
patients provided a reason to believe otherwise. IS could, by disrupting infection of cells by 
HIV virions or by suppressing T-cell activation, even be beneficial in this patient group.
79
  
The human immunodeficiency virus infects a memory CD4+ T-cell with a concomitant CCR5 
expressed on the cell surface. The central pool of CD4+ cells does not express CCR5 and are 
relatively protected from infection until they become activated. As the cells are infected pro-
inflammatory cytokines are released and during chronic HIV-infection there is continuous 
immune hyperactivation of T-cells.
85
 The persistent viremia together with the consequent 
depletion of CD4+/CCR5 cells seems to be especially prominent in the gut mucosa (GALT) 
leading to translocation of bacteria through the intestinal epithelium. This exposes the patient 
to inflammatory mediators such as bacterial lipopolysaccharides further stimulating the 
ongoing immune reaction.
86
 An antibody response can further worsen the situation by binding 
to the infected cells causing complement activation and immune complex deposition.
87
 Even 
those effectively treated with ART have a continuous chronic inflammatory response which 
may be a cause of tissue damage.
79 
 
Studies have shown that the cellular protein cyclophilin A is required for maturation of the 
HIV-1 and subsequently for its ability to infect other cells.
88, 89
 Both cyclosporin A (CsA) and 
tacrolimus (Tac) have been demonstrated to impact HIV replication. In vitro studies showed 
how CsA binds to cyclophilin A and suppresses IL-2 mediated lymphocyte activation, 
decreases infectivity of naive cells and inhibits viral production in chronically infected cells.
90
 
Tac interfere only with growth of chronically infected cells, but do not decrease infectivity as 
seen with CsA.
91
 Sirolimus reduces CCR5 expression and causes suppression of the HIV-1 
replication in vitro at concentrations far lower than the therapeutic dose for 
immunosuppression in kidney transplantat recipients.
92
  
One study compared the treatment of patients newly diagnosed HIV treated with only 
HAART and a group treated with HAART and concomitant cyclosporin A. At the end of the 
study viral replication was equally suppressed, but the CD4+ cell count was significantly 
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higher in the group treated with both HAART and cyclosporine. This finding suggests that 
immunosuppression prevent the inflammatory trigger to cause activation of central CD4+ 
cells and thus also prevent them from being infected, could have a beneficial effect.
84
 
 
Outcome after transplantation 
In the pre-HAART era, the outcome after solid organ transplantation in the HIV-infected 
patient was poor, leading to shorter AIDS-free interval and frequently death due to AIDS or 
AIDS-related complications.
93-95 
The pilot study performed by Stock et al. in 2007 challenged 
the odds of the previous reports. This was done in the setting of better control of HIV, since 
the introduction of HAART in 1996, and more effective prophylaxis and management of 
opportunistic infections.
96
  
Kumar et al. performed one of the earlier studies on the outcome of renal transplantation in 
the HIV-positive group. Clinical acute rejection occurred more frequently than in the non-
HIV group and they speculated that the reason might be that they used lower level of 
immunosuppression to avoid opportunistic infections. Ultimately the graft survival was 
comparable to other high risk groups, and the patients had better survival than those who were 
maintained on dialysis. They noted that the majority of their subjects were African-American 
(97%) and that half of the kidneys came from marginal donors
68
, factors that on their own are 
associated with a lower rate of graft survival.
97
  
 
Qiu et al. used information from the UNOS Renal transplant registry to study the outcome 
after renal transplantation when one of the donor kidneys went to a HIV-positive recipient and 
the other to a HIV-negative recipient. Although they admitted low power, the study showed a 
statistically significant survival rate that was similar in both patient groups. The survival was 
even slightly better in the HIV-positive group, possibly due to stricter selection criteria, the 
fact that they in general were younger or that they had lower levels of PRA. The HIV-positive 
cohort had higher creatinine values which could be due to the nephrotoxic effect of ART that 
can occur with the intricate interactions with the immunosuppressive therapy.
98
 
Roland et al. conducted a prospective study of liver and kidney transplantation in the HIV-
infected patients and recorded the patient, graft and HIV related outcomes.  With a median 
follow up of three years, patient survival was approximately 94 % and graft survival was 83 
% after one and 3 years, respectively. The reasons for rejection were severe acute rejection, 
chronic rejection and vascular thrombosis. Both patient and graft survival were similar to the 
general population transplanted  at the age of 65 or older, as reported from the Organ 
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Procurement and Transplantation Network (OTPN)
99
. Candida esophagitis was reported in 
one patient with diabetes, previously treated with thymoglobulin for an event of acute 
rejection, but who recovered with antifungal treatment. The cumulative incidence of allograft 
rejection at 1, 2 and 3 year reached 52 % in the kidney transplant recipients. Hazard ratios 
were increased and found statistically significant only for age and panel reactive antibodies 
(PRA) levels at transplant. Other factors, such as most recent CD4+ cell count, antigen 
mismatch, use of ART and delayed initiation of cyclosporine were speculated to have 
influence, but could not be proven due to the low power of the study. They made the 
observation that the patients with episodes of rejection had a higher median creatinine 
value.
100
  
 
The Croatian case report shows similar results with an HIV-infected patient under good 
control prior to transplantation, standard induction therapy (prednisolone, tacrolimus, 
mycophenolate mofetil and basiliximab). The patient experienced coagulation abnormalities 
with bleeding despite normal coagulogram, Non ST-elevation myocardial infarction 
(NSTEMI), psuedomonas pneumonia and borderline acute rejection requiring a period of 
dialysis. The patient improved with three boluses of methylprednisolone and was ready for 
discharge two months after transplantation. The patient was under the care of a 
multidisciplinary team with nephrologists, urologists and infectologists.
101
  
An evidence-based analysis on the outcome of solid organ transplantation in the HIV-positive 
patient concluded that the risk of death after kidney transplantation did not differ between 
HIV-positive and -negative patients although they found the level of evidence to be very low. 
The same low evidence made the result of insignificant difference in risk of acute rejection 
between HIV-positive and HIV-negative uncertain.
102
  
 
Infection 
The majority of infections reported after kidney transplantation have typically not been 
opportunistic in nature,
68,
 
96
 but the use of thymoglobulin has been associated with 
opportunistic infections in several studies.
96, 100
  
Proper prophylaxis against opportunistic infections is essential. Today these include 
cytomegalovirus, toxoplasmosis, pneumocystis carinii pneumoniae, mycobacterium avium 
complex, cryptococcosis and histoplasmosis.
41
 Additionally recommended prophylaxis 
include tuberculosis, hepatitis A and B, Streptococcus pneumoniae, chicken pox and 
Hemophilus influenzae B.
77 
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Table 4. Opportunistic infections and their treatment. Reproduced with the permission from 
Wolters Kluwer Health.
41
 
Condition Primary prophylaxis
a
 Secondary prophylaxis
b
 
Pneumocystis carinii pneumonia Indicated for life; Initiate 
immediately posttransplant 
Preferred: TMP-SMX 
Alternative: dapsone, if not G6PD 
deficient, atovaquone 
Indicated for life; Initiate 
immediately posttransplant 
Preferred: TMP-SMX 
Alternative: Dapsone if not G6PD 
deficient, atovaquone 
Toxoplasmosis Toxoplasmosis IgG-positive 
patients with CD4+ T cell count ≤ 
200  
Preferred: TMP-SMX 
Alternative: atovaquone, 
sulfadiazine + pyrimethamine + 
leucovorin 
CD4+ T cell count <200 cells/mL.  
Discontinue when CD4+ cell count 
is >200 cells/mL for 3-6 months 
Alternative: atovaquone, 
sulfadiazine + pyrimethamine + 
leucovorin 
Mycobacterium avium complex Indicated when CD4+ T cell count 
is ≤ 50 cells/mL. Discontinue when 
CD4 count is above 100 cells/mL 
for 3-6 months. 
Preferred: azithromycin 1200mg 
weekly 
Alternative: clarithromycin 
Cell count 50 cells/mL 
 
Discontinue when CD4 count is 
above 100 cells/mL for 3-6 months. 
 
 
Alternative: clarithromycin ' 
ethambutol 
Cytomegalovirus No HIV-specific indication Cell count 75-100 cells/mL 
Discontinue when CD4+ T cell 
count is above 100-200 cells/mL 
for 3-6 months. 
Preferred: valganciclovir 
Alternative: foscarnet, cidofovir 
Cryptococcosis, extrapulmonary No HIV-specific indication CD4+ cell count below 200 
cells/mL. 
Discontinue when CD4+ cell count 
is above 200 cells/mL for 3-6 
months
c 
Fluconazole 
Histoplasmosis No HIV-specific indication Continue regardless of CD4+ cell 
count  
Itroconazole 
 a No history of the infection 
 b  Prior history of the infection 
 c Secondary prophylaxis should also be reinstitued immediately posttransplant for 1 month and 
 during the treatment of acute rejection for 1 month following completion of acute rejection 
 therapy. If the CD4+ T cell count is suppressed, continuation should be guided by the CD4+ T 
 cell count.  
Rejection 
The rate of rejection is much higher than in that of the general population, sometimes as high 
as two or three times. Despite this number, the overall graft survival is not different from the 
non-HIV transplanted.
77
 It is believed that the immune system of an HIV positive patient is 
dysregulated rather than just suppressed. This is supposed to be the cause at least in the cases 
of very early rejection.
96
 Another theory is that the complex drug interactions cause 
fluctuations in the blood concentrations of the immunosuppressive therapy opening up to 
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rejection.
96, 100
 Today, most of the episodes of rejections are susceptible to therapy with either 
corticosteroids or, in more severe cases, thymoglobulin.
79
  
 
Drug interactions 
Drug interactions between IS and ART are a big concern in the transplanted HIV patients. 
The interactions are unpredictable and are not the same even within groups of ARTs. The 
impact of these uncertain drug levels can lead to either toxicity or suboptimal 
immunosuppression. The main interactions seem to be between calcineurin inhibitors (CNI) 
and protease inhibitors (PI). Many of the PIs inhibit CYP-450 3A, which are responsible for 
metabolizing both immunosuppressants and other ARTs.
103
 The efflux transporter P-
glycoprotein (P-gp) is predominantly found on the apical side of intestinal and hepatic 
epithelial cells and act to decrease absorption and increase excretion of its substrates. 
Normally in intestinal cells, P-gp and CYP3A4 act to decrease absorption and increase drug 
metabolism. Concomitant administration of immunosuppressant and ART acting on these 
processes is expected to decrease their metabolism while increasing their uptake, leading to 
higher systemic blood levels.
104
 P-glycoproteinis is another substrate for the PIs
105
. Frassetto 
et al. 2013 described the pharmacokinetics of concomitant administration of ART and IS in a 
longitudinal study. In the first three months after transplant when CsA was given together 
with a PI only 1/10 of the dose necessary for the non-HIV patients was enough to reach 
therapeutic blood levels. The dose of CsA had to be higher when given with Efivirenz (EFV) 
than when given together with Nevirapine (NVP), and both were significantly higher than if it 
was administered with PIs in week 2-12. Bioavailability of CsA, when given concomitantly 
with EFV increased over time, whereas there was no time dependent change when co-
administered with PIs or NVP. In a combination dose of PI+NVP the CsA dose increased by 
about 30 % with almost unchanged AUC. With tacrolimus the dose had to be lowered 
significantly when given together with PIs with exposure increasing 10-fold, but was not 
affected significantly by NVP or EFV. The increased bioavailability of TAC with PI was 
significantly higher than for CsA.
104 
 
A higher level of IS is associated with a lower risk of rejection. Frasetto et a. found that 
giving a PI (CYP450 inhibitor) and a non nucleoside reverse transcriptase inhibitor (NNRTI) 
(CYP450 inducer) together, did not produce the estimated intermediate effect on the IS 
metabolism. Due to different potencies, the additional effect on the P-gp and probably several 
unknown transporters, the resulting trough levels are unpredictable. The conclusion was that 
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EFV and NVP affected CsA differently over time, making predictions according to group 
inaccurate.
104
  
 
When using PIs and CNIs, the dosages of CNIs must be significantly reduced or the dosing 
free intervals extended. Tacrolimus is a substrate for both CYP 450 3A and P-glycoprotein. 
The latter is responsible for the drug's entry into lymphocytes, through the blood brain barrier 
and into tissues. There seems to be almost identical features with cyclosporine, but it has been 
less extensively tested in vitro. There are also studies showing different tacrolimus drug 
interactions between gender and ethnicities.
106 
Sirolimus and Everolimus are also substrates 
for P-450 and P-glycoprotein and have been reported to react similarly, but only limited data 
exist.
107 
 
The non-nucleoside reverse transcriptase inhibitors NNRTs are p-450 substrate inducers and 
can lead to increased metabolism of CNIs or sirolimus with consequent sub-optimal levels in 
the blood.
107
 The NRTs are not substrates for the p-450 system, but may contribute to both 
anemia and neutropenia. This together with the effect of some immunosuppressive drugs, may 
cause severe leukopenia and CD4+ cell depletion.
79
  
 
The active metabolite of MMF, mycophenolic acid, interferes with the conversion of inosine 
monophosphate (IMP) to guanosine monophosphate (GMP). Some in vitro studies showed 
several interactions between MMF and ART, including abacavir, didanosine and tenofovir.
79
 
Apart from its interactions it seems as though the depletion of GMP, the substrate for reverse 
transcriptase in the virus infected cells, might prevent replication of the virus and even induce 
apoptosis of activated CD4+ cells in vitro with the result of hampering the infection.
109
 
Glucocorticoids are, like the NNRTs, inducers of the p-450 system. The tapering of the 
steroid dose that typically starts after transplantation may be accompanied by changes with 
increased blood concentrations of CNIs and decreased CD4+ cell counts. This consequently 
puts the patient at a higher risk of nephrotoxicity and infection.
109
  
 
Drug selection in the transplant recipient 
Different immunosuppressive regimens have been tried and so far there is no convincing 
evidence that one is superior to the other.
77
 In addition to the usual challenge of balancing the 
risk of rejection and opportunistic infections this patient group have the drug interactions 
between the immunosuppressants and the ART.
79
 For the induction therapy, many are trying 
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to avoid lymphocyte-depleting drugs, e.g. thymoglobulin, because it can cause a very low 
CD4+ T cell count for an unpredictable duration of time
77
. Several authors have noticed an 
increased frequency of infections with this drug.
96
 High immunologic risk patients usually 
receive a more aggressive induction therapy pre-transplantation; typically they receive 
antithymocyte globulin or an IL-1 receptor antibody.
110
 The use of glucocorticoids and IL-2-
inhibitors made lymphocyte-depleting drug-sparing regimens possible.
77
 
The maintenance therapy today typically consists of three components: a CNI (e.g. 
cyclosporine or tacrolimus), an anti-metabolite (e.g. mycophenolate mofetil) and 
corticosteroids.
77,79
 CsA is commonly favored because of its positive effect on both 
antiretroviral and immunosuppressive effects.
79, 90, 91
 It has been preferred over TAC in part 
due to the latter having an increased risk of inducing glucose intolerance,
 77, 96, 101 
 but recent 
evidence suggests that CsA is associated with rejection episodes, although without loss of 
graft.
98
 MMF deplete intracellular nucleotides and thus have antriretroviral properties and 
synergistic effects with certain NRTs, such as didanosine and abacavir.
30, 77
  
Sirolimus is, in addition to downregulating the CCR5 expression, an anti-proliferative agent 
that is useful in the treatment of Kaposi sarcoma and it has been suggested that it could be 
used beneficially in cancer occurring post-transplant. It can be a good alternative in those 
experiencing cyclosporine toxicity or decreased renal function of other etiology.
77
  
There are five groups of antiretroviral drugs: nucleoside reverse transcriptase inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTIS), protease inhibitors (PI), 
entrance inhibitors and integrase inhibitors. Usually a combination of three is used and the 
goal is to set a regimen that can be continued post-transplantation. Tenofovir is associated 
with both acute and chronic declines in renal function and should be used with caution in 
transplant recipients.
79
 Combination pills usually have to be avoided in patients with impaired 
kidney function due to the need to individualize dosing regimens of the different drugs and 
requirement to adjust them over time.
104
  
CCR5 is a co-receptor needed for HIV to infect CD4+ T cells and those who are homozygous 
for CCR5Δ32 mutation causing a non-functioning receptor are resistant to HIV infection. This 
receptor was found to be upregulated in cases of acute rejection and drugs deactivating this 
receptor has become of interest in transplantation medicine.
113
 Fischereder et al. studied the 
outcomes after renal transplantation in patients homozygous for CCR5Δ32 mutation, 
heterozygous and homozygous wild-type. The results were statistically significant with 
improved graft survival in the CCR5Δ32 homozygous group compared to the heterozygous 
and those with wild-type mutation.
112 
Heidelhain et al. got similar results.
113
 The CCR5-
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antagonist maraviroc, (ART), was tested in patients receiving hematopoietic stem cell 
transplantation (HSCT) and proved to have lower incidence of visceral GVHD. Maraviroc 
hampers chemotaxis without interfering with the function of the T cells.
114
  
 
Corticosteroid-sparing regimen 
Corticosteroids are a part of the maintenance therapy after transplantation in many regimens, 
but have an increased risk of cardiovascular events.
115
 Early withdrawal regimens have been 
tried in HIV-negative kidney transplantation. Knight et al. performed a meta-analysis of 
kidney transplantation where steroid avoidance or withdrawal (SAW) protocol had been 
followed. They found an increased risk of acute rejection episodes, although with only a 
marginal effect on graft survival and that cardiovascular risk factors, measured by HTN, DM 
and hypercholesterolemia, were greatly decreased.
116
 Very early steroid withdrawal (VESW), 
when corticosteroids is removed before day three post-transplantation, was studied. In a meta-
analysis of RCTs of renal transplantations and VESW protocol, an increased rate of acute 
rejection was found, although they were mild episodes that were mostly amenable to therapy. 
They found that this difference lost significance for the patients receiving TAC, but 
maintained for those on CsA. VESW was associated with delayed graft function (DGF). 
Cardiovascular risk factors were significantly reduced with this protocol. In conclusion it was 
safe to withdraw corticosteroids early, but longer than three days would decrease the risk of 
DGF.
117
 Muthukumar et al. tried SAW in the kidney transplantations of 11 consecutive HIV-
infected patients. The authors used an anti-thymocyte globulin agent as the primary induction 
agent, intravenous methylprednisolone day 0-4 and maintenance therapy with tacrolimus and 
mycophenolate mofetil without any corticosteroids. All patients were low-risk and maintained 
on HAART both before and after transplantation. One year patient survival was 100% and 
allograft was 91%; at three years it was 90% and 81 % respectively. One patient died of 
uncertain causes; it was believed to be of cardiovascular reason, but the subject had a stable 
graft function on the last check up. The causes of rejection were primary non-function and 
acute rejection. Two episodes of acute rejection were treated with pulse methylprednisolone, 
immunoglobulins and plasmapheresis, but both grafts failed despite this. No progression of 
HIV-disease was reported, measured by increased number of viral copies. Complications 
included infections and cancer, all successfully treated. Overall the graft and patient survival 
were comparable to larger studies done in the HIV-positive population with non-steroid 
sparing treatment and with seemingly reduced cardiovascular risk. No patient had any change 
in weight, blood pressure or lipid lowering drugs and no new onset of diabetes mellitus after 
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transplant (NODAT). The results were promising, but should be interpreted with caution due 
to its low power and lack of control group.
118
  
 
Combined liver and kidney transplantation in the HBV/HCV-HIV infected patient 
Many patients with HIV are co-infected with HBV or HCV, in some studies as high as 50 %, 
due to a common route of transmission.
102
 The infections affect each other; the HCV infection 
can promote an antibody-antigen complex glomerulonephritis and cause ESRD and the 
treatment of HIV with ART can hasten the progression to end-stage liver disease in the person 
with HCV-infection. The HCV/HIV co-infected patient has a poorer response to anti-hepatitis 
medication, mostly pegylated interferon (IFN) and ribavirin, and they have many interactions 
with ART. Post-renal transplantation immunosuppression is believed to activate HCV 
replication and accelerate the development of end-stage liver disease. Furthermore IFN 
therapy is contraindicated in the renal transplant patient.
119
 End stage liver disease, many 
times due to HCV-infection and its sequelae (cirrhosis, liver failure and hepatocellular 
carcinoma) is now a leading non-AIDS cause of death in the HIV-positive patient in the 
developed world.
77,120
 Patients with HIV-infection and concomitant liver failure have a poorer 
pre-transplant survival rate than the HIV-negative corresponding group.
121
 HBV infection has 
no negative effect on graft- or patient survival after kidney transplantation. Patients with a co-
infection of HCV have shown variable results after transplantation. The Ontario Health 
Technology Assessment Series evidence based analysis, made in 2010, found that the risk of 
death after transplantation was 2.8 times higher in the co-infected (HIV+/HCV+) than the 
mono-infected (HIV-/HCV+).
102
  One study attributed the lower graft and patient survival to 
older age, combined liver-kidney transplantation, an anti-HCV-positive donor and a BMI 
<21kg/m
2
. Without these factors the survival rates were the same as after transplantation in a 
HCV mono-infected patient. Many patients experience HCV recurrence following 
transplantation contributing to the lower survival.
77
 The new anti-viral drugs for HCV, called 
direct-acting antivirals have so far limited experience, but show promising results. Concerns 
regarding drug-drug interactions with the HIV ART still exist.
122
  
Eligibility criteria are somewhat different in this group than the monotransplant kidney 
patients; In some combined liver-kidney transplantations the viral load can be accepted to be 
higher if the patient cannot tolerate HAART due to poor liver function and drug associated 
hepatotoxicity.  BMI should be > 21kg/m
2
.
73
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Discussion 
The history of HIV/AIDS is a relatively short one. It appeared in the 1980’s and a diagnosis 
meant a certain and imminent death and today it can be considered to be a chronic disease. 
Many times the disease was associated with homosexuals, intravenous drug abusers and black 
people, but later spread to transplant recipients and other groups of society. Since the 
introduction of the first anti-HIV drug in 1987, and later HAART in 1995, the future of 
HIV/AIDS patients changed quickly. In the developed world the morbidity in this population 
has become more similar to the general population with hypertension, diabetes and end-organ 
failure. This group is even more susceptible to these conditions due to side effects of the 
cART. Transplantation as treatment of end-organ failure in the HIV-positive patient has long 
been considered futile. There have been many and major obstacles to successful 
transplantation, but they are being overcome one at the time. In the beginning the short life 
span of the infected person made transplantation a dangerous procedure that did not improve 
neither the quality of life nor the possibility of survival of the patient and was thus considered 
a waste of scarce organs. Many feared that the immunosuppression from the transplantation 
therapy would cause unlimited viral replication and hasten the progression to AIDS and death. 
HAART allowed better controlled HIV and some started performing transplantation in well 
regulated patients. The results were significantly better than before, but still lower than the 
general population. It was speculated that this could be because they received suboptimal 
immunosuppression, organs from marginal donors and that they were mostly Black, all which 
historically were associated with a poorer outcome. The realization that immunosuppressive 
treatment might actually have a beneficial effect on HIV has increased the willingness to 
perform transplantation in this group. With time knowledge, novel drugs and treatment 
regimens, and experience of the treating physicians from all relevant fields in medicine led to 
better results. Still, acute rejection episodes are more common in this population, but are 
rarely leading to graft failure.  
The HIV-positive patient population with ESRD, who require and is eligible for 
transplantation, is still relatively small and scattered over the world, making it difficult to 
attain large power studies to provide strong evidence. The research that are done using 
information from bigger data registries often encounter problems of missing data and 
inconsistent use of parameters, making comparisons difficult.  
One of the issues today regarding transplantation is concerning optimal drug regimen. 
Complex drug interactions that are different between and within groups of drugs regarding 
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metabolism, excretion and bioavailability require regular and continuous checkups of drug 
concentrations in blood. A multidisciplinary team including infectious disease specialists and 
nephrologists is recommended for a better understanding and an optimal choice of drugs. The 
improved survival rates and graft function have allowed cardiovascular and other long term 
risk factors to be taken into account and different types of early corticosteroid withdrawal 
protocols are being tried. 
An HIV-positive patient with end-organ failure is less likely to end up on the transplant list 
than his HIV-negative counterpart. The diagnosis of HIV is associated with a social stigma 
that can lead to less HIV positive patients to receive transplants. In countries like the United 
States, with a large Black population there is an underrepresentation of this subgroup even 
within the HIV-positive transplant recipients. Reluctance to revealing their HIV status to the 
donor and less awareness of the benefits of this treatment option were identified as possible 
causes. Specialized support groups and educational programs might be needed for these 
patients to learn about their options and be able to consider transplantation in light of the 
current research.  
 
Conclusion 
The studies performed with renal transplantation in the HIV-positive patients since the 
introduction of HAART has demonstrated continuously improving survival of both graft and 
patient, and today it is similar to those of the HIV-negative population. The question of 
whether it is beneficial to perform renal transplantation in the HIV-positive population were 
affirmative in the later studies, reviews and meta-analyses although they all admitted to low 
power due to small study sample sizes. In conclusion, more research has to be done to gain 
greater level of evidence, but regarding the disease and its management we have come to a 
point where the outcome of renal transplantation is similar to the general population and 
should be offered to anyone fulfilling the criteria.  
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